2015
Variability in utilization of drug eluting stents in United States: Insights from nationwide inpatient sample
Panaich SS, Badheka AO, Arora S, Patel NJ, Thakkar B, Patel N, Singh V, Chothani A, Deshmukh A, Agnihotri K, Jhamnani S, Lahewala S, Manvar S, Panchal V, Patel A, Patel N, Bhatt P, Savani C, Patel J, Savani GT, Solanki S, Patel S, Kaki A, Mohamad T, Elder M, Kondur A, Cleman M, Forrest JK, Schreiber T, Grines C. Variability in utilization of drug eluting stents in United States: Insights from nationwide inpatient sample. Catheterization And Cardiovascular Interventions 2015, 87: 23-33. PMID: 26032938, DOI: 10.1002/ccd.25977.Peer-Reviewed Original Research
2013
Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years
Forrest JK, Lansky AJ, Meller SM, Hou L, Sood P, Applegate RJ, Wang JC, Skelding KA, Shah A, Kereiakes DJ, Sudhir K, Cristea E, Yaqub M, Stone GW. Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years. The American Journal Of Cardiology 2013, 111: 1580-1586. PMID: 23499270, DOI: 10.1016/j.amjcard.2013.01.330.Peer-Reviewed Original ResearchConceptsSPIRIT IV trialMajor adverse cardiac eventsAdverse cardiac eventsClinical outcomesXIENCE VTarget lesionsCardiac eventsNovo native coronary artery lesionsIschemia-driven target vessel revascularizationTwo-year clinical outcomesNative coronary artery lesionsSPIRIT IIISide branchesXIENCE V EverolimusTarget lesion failureTarget vessel revascularizationCoronary artery lesionsPercutaneous coronary interventionSuperior clinical outcomesTreatment of patientsCoronary stent systemDrug-eluting stentsDiverse patient populationsEverolimus-ElutingSPIRIT IV